Adherence to National Comprehensive Cancer Network Guidelines for BRCA Testing Among High Risk Breast Cancer Patients: A Retrospective Chart Review Study
Affiliations
- PMID: 32518611
- PMCID: PMC7275608
- DOI: 10.1186/s13053-020-00144-z
Abstract
Background: Testing for BRCA variants can impact treatment decisions for breast cancer patients and affect surveillance and prevention strategies for both patients and their relatives. National Comprehensive Cancer Network (NCCN) guidelines recommend testing for patients at heightened risk of BRCA pathogenic variant. We examined the BRCA testing rate among high risk breast cancer patients treated in community oncology practices.
Methods: We conducted a retrospective medical chart review among community-based US oncologists using a physician panel approach. High risk breast cancer patients with a known family history of cancer and diagnosis with breast cancer at age ≥ 18 years between January 2013-October 2017 were included. We assessed the proportions of patients tested for BRCA variants in accordance with NCCN guidelines.
Results: Charts from 63 physicians, averaging 16 years of practice, were included; 97% were medical oncologists and 66.7% had a genetic counselor in their practice. We analyzed data for 410 randomly-selected patients with mean age of 52 years; 95% were female, 74% were White, and 19% had Ashkenazi Jewish ancestry. Among all patients, 94% were tested for BRCA variants. The testing rate ranged from 78 to 100% in various high risk groups; lower rates were observed among Black patients (91%), men (92%), and patients meeting NCCN criteria based on family history of male breast cancer (78%) and prostate cancer (87%). We observed a higher testing rate in patients treated by physicians with a genetic counselor in their practice (95% versus 91%).
Conclusions: Adherence to NCCN BRCA testing guidelines is high in this group of predominantly medical oncologists with extensive experience, with a high proportion having a genetic counselor in practice. Testing rates can be improved in patients with risk factors related to male relatives. High level of compliance to guidelines in a community setting is possible with a delivery model for genetic counseling and testing.
Keywords: BRCA testing; BRCA variant; Breast cancer; Genetic testing; NCCN guidelines.
© The Author(s) 2020.
Conflict of interest statement
Competing interestsPJB, MD and MSD are employees of Analysis Group Inc., a consulting company that has received consultancy fees and research funds from AstraZeneca to conduct this study. TO, RS and HY are employees of AstraZeneca.
Similar articles
- Rate of BRCA mutation in patients tested under NCCN genetic testing criteria.Am J Surg. 2020 Jan;219(1):145-149. doi: 10.1016/j.amjsurg.2019.06.012. Epub 2019 Jun 19.PMID: 31255259
- Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals.Am J Clin Oncol. 2016 Aug;39(4):363-7. doi: 10.1097/COC.0000000000000073.PMID: 24710121
- BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.Fam Cancer. 2017 Jan;16(1):41-49. doi: 10.1007/s10689-016-9921-5.PMID: 27589855
- A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer.Cancer Manag Res. 2019 Mar 22;11:2321-2337. doi: 10.2147/CMAR.S189627. eCollection 2019.PMID: 30962720 Free PMC article. Review.
- Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.Adv Ther. 2016 Feb;33(2):129-50. doi: 10.1007/s12325-016-0281-1. Epub 2016 Jan 25.PMID: 26809252 Review.
No hay comentarios:
Publicar un comentario